Recombinant Human 17-beta-hydroxysteroid dehydrogenase 13 (HSD17B13)

To produce recombinant Human HSD17B13 protein, a well-established recombinant DNA technology is the key. A DNA template of HSD17B13 was constructed with N-terminal 6xHis tag & C-terminal Myc tag using the technique. Once the template was made, the recombinant Human HSD17B13 protein could be produced with it efficiently. CUSABIO has built a strict QC system to ensure quality. The expression region is 20-300aa of the Human HSD17B13. The purity of this recombinant is 90% determined by SDS-PAGE.

HSD17B13 (SCDR9) is a protein coding gene that encodes 17-beta-hydroxysteroid dehydrogenase 13. According to some studies, HSD17B13 may have the following features.
Loss-of-function variants of HSD17B13 are associated with a reduced risk of chronic liver disease and progression from steatohepatitis to steatohepatitis. Inactivation of HSD17B13 was not associated with increased hepatic triglyceride content and provided protection against chronic liver disease. HSD17B13, a hepatic retinol dehydrogenase, is associated with histological features of nonalcoholic fatty liver disease. Lack of Hsd17b13 did not protect mice from an obesogenic diet. High risk of fatty liver amplifies the alanine aminotransferase-lowering effect of HSD17B13 variants. Genetic variants in HSD17B13 reduce the risk of cirrhosis and hepatocellular carcinoma in alcohol abusers.